BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Otsuka 'checks all the boxes' for Akebia in potential $1B+ vadadustat deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Otsuka 'checks all the boxes' for Akebia in potential $1B+ vadadustat deal
Dec. 21, 2016
By
Marie Powers
No Comments
While most analysts and investors were focused on its discussions with potential European partners, Akebia Therapeutics Inc. turned to Asia, again, for a U.S. development and commercialization collaborator for its lead candidate, vadadustat.
BioWorld